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Abstract
Background: Major depressive disorder (MDD) has major consequences for both patients and
society, particularly in terms of needlessly long sick leave and reduced functioning. Although
evidence-based treatments for MDD are available, they show disappointing results when
implemented in daily practice. A focus on work is also lacking in the treatment of depressive
disorder as well as communication of general practitioners (GPs) and other health care
professionals with occupational physicians (OPs). The OP may play a more important role in the
recovery of patients with MDD. Purpose of the present study is to tackle these obstacles by
applying a collaborative care model, which has proven to be effective in the USA, with a focus on
return to work (RTW). From a societal perspective, the (cost)effectiveness of this collaborative
care treatment, as a way of transmural care, will be evaluated in depressed patients on sick leave
in the occupational health setting.
Methods/Design: A randomised controlled trial in which the treatment of MDD in the
occupational health setting will be evaluated in the Netherlands. A transmural collaborative care
model, including Problem Solving Treatment (PST), a workplace intervention, antidepressant
medication and manual guided self-help will be compared with care as usual (CAU). 126 Patients
with MDD on sick leave between 4 and 12 weeks will be included in the study. Care in the
intervention group will be provided by a multidisciplinary team of a trained OP-care manager and
a consultant psychiatrist. The treatment is separated from the sickness certification. Data will be
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BMC Health Services Research 2008, 8:99 http://www.biomedcentral.com/1472-6963/8/99collected by means of questionnaires at baseline and at 3, 6, 9 and 12 months after baseline. Primary
outcome measure is reduction of depressive symptoms, secondary outcome measure is time to
RTW, tertiary outcome measure is the cost effectiveness.
Discussion: The high burden of MDD and the high level of sickness absence among people with
MDD contribute to the relevance of this study. The intervention is an innovative approach, with
trained OPs in a new role as care managers in the treatment of MDD. If this intervention proves
to be cost-effective, implementation will be very relevant for individual patients as well as for
society.
Trial registration: ISRCTN78462860
Background
The burden of major depressive disorder (MDD) on the
level of sickness absence in the community is huge, for
society as well as for individual patient MDD is therefore
responsible for enormous costs, for patients, companies
and society as a whole. In the global burden of disease
study, MDD is even expected to be one of the top 2 lead-
ing causes of disability-adjusted life years in 2020 [1],
with a lifetime prevalence of 15.4 % and a 12-month prev-
alence of 5.8 % for MDD [2]. Moreover, 80% of the costs
of this disorder are due to production loss [3,4]. In the
Netherlands, people with MDD are absent from work 8 to
9 times more often than people without the disorder
[5,6]. These high prevalences and costs, in addition to the
fact that MDD with its frequent relapses is considered to
be a chronic disorder, contribute to the enormous impli-
cations MDD has for society. Occupational physicians
(OPs) aim to play a larger role in the care for workers with
depression [7,8].
Sickness absence
Prolonged absence from work is called the major public
health problem in the western world, which leads to
social deprivation of patients and their families [9]. The
contribution of psychiatric disorders to sickness absence
has increased and accounts for more incapacity benefit
claims than musculoskeletal disorders. Among psychiatric
disorders, disorders such as depression and anxiety, rather
than psychotic disorders, contribute most to this rising
sickness absence [9]. Moreover, the adverse economic
effects related to depression are underestimated when
only looking at absenteeism, because besides absentee-
ism, MDD is also associated with persistent presenteeism
(reduced at-work job performance and productivity) [10-
12].
The ability to work is an important aspect of peoples qual-
ity of life [13]. For patients, prolonged absence from work
increases the risk of isolation and reduces meaningful
activity [14,15]. Furthermore, the patient may become
anxious to return to work, doubting his own competence
and fearing that co-workers will respond with resentment
or pity [14]. Longer absences are associated with a reduced
probability of eventual return to work and with subse-
quent economic and social deprivation [9,14]. Thus, con-
sidering the implications for the patient's quality of life
and the huge costs incurred by sickness absence, return to
work (RTW) is very important.
Current research shows that a reduction in symptoms
does not automatically lead to recovery of functioning at
work [12,16-18]. In order to achieve a more rapid and
more lasting RTW in patients with mental disorders, a
focus on functioning at work is essential [16-18].
Current usual care for MDD
Although evidence-based treatments are available [19], in
real life, there are many obstacles [20]. First, the diagnos-
tic process is hampered by the fact that 70% of depressed
subjects present with physical symptoms to their general
practitioner (GP), and not depressive symptoms [21]. Sec-
ond, due to the nature of their condition, patients with
MDD are less willing to accept their diagnosis, and third,
do not adhere to treatment recommendations [19].
Fourth, effective methods of treatment are applied insuffi-
ciently [19,20], and care-providers do not adhere to evi-
dence-based treatment algorithms and fifth, there is a lack
of active monitoring [20,22].
Next to the insufficient implementation of the treatment
of MDD, the RTW strategies of workers sick listed due to
mental health problems are sub-optimal. There is a lack of
communication and collaboration by Dutch OPs and GPs
in the medical diagnosis and management of these
employees. Dutch GPs and OPs differ in their medical
diagnoses and medical management of these employees
[23]. Also, GPs have a more advisory role and may pay
insufficient attention to working conditions and work
related interventions. This is a consequence of the fact that
Dutch GPs, unlike GPs abroad, do not certify sickness
absence and therefore are not obliged to pay attention to
work aspects [23-25]. Lack of coordination and sub-opti-
mal care and particularly lack of active monitoring by a
care manager hampers the recovery towards functioningPage 2 of 12
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essarily high costs for subjects and society [26].
Collaborative Care
Many single treatment modes for MDD have proved to be
efficacious in the controlled research setting. However,
they show disappointing results when implemented in
daily practice. Therefore, more complex or more powerful
methods of treatment are needed, adapted to the individ-
ual patient and accompanied by improvement in adher-
ence [27,28]. In the USA, the collaborative care model
turned out to be an effective answer to this problem [29-
32]. In their meta-analysis, Gilbody et al. [33] confirmed
the effectiveness of collaborative care in improving out-
comes in depression. They reported the need for studies
aimed at clarifying how collaborative care can be imple-
mented best in European health care systems.
One of the hallmarks of collaborative care, broadly
defined by Bower et al. [34] as a multifaceted organisa-
tional intervention, is the introduction of a new role, the
case- or care manager. We intend to introduce this care
manager in the occupational setting. The care manager
coordinates care and assists in the management of
patients with depressive disorders [34]. Also, in collabora-
tive care there is collaboration between different health
care professionals, such as GPs, psychiatrists and care
managers. Collaborative care not only encompasses col-
laboration between health care professionals, as a way of
transmural collaboration, but also between doctor and
patient, in that the active participation of the patient is
characteristic for collaborative care [30,35]. In addition,
in collaborative care the progress of individual patients is
continuously evaluated [34]. The organizational aspects
of collaborative care are probably partly the mediating
factors in the effect of this model [36].
The intervention
In the present study, the collaborative care model is
applied in the occupational health setting in the Nether-
lands. We intend to improve attention for work issues in
the care/curative sector as well as the lack of communica-
tion in the management of MDD by using a collaborative
care model with a focus on RTW.
Given that sickness absence is not only due to the per-
sonal characteristics of the patient, but is also a result of
interaction with the environment (such as the workplace
and the health care system), these factors should also been
taken into account in the intervention [37]. For that rea-
son, in the present study a workplace intervention (aimed
at the workplace) will be combined with interventions
aimed at the individual (PST, medication, self help) in a
transmural care model (aimed at the health care system).
Methods/Design
Objectives
Primary aim of this randomised controlled trial (RCT) is
to evaluate the effectiveness of collaborative care versus
care as usual (CAU) in terms of severity of depressive
symptoms in the treatment of MDD in the occupational
health care setting. Secondary aim is to evaluate the effec-
tiveness of the intervention in terms of RTW. Third, the
cost-effectiveness will be evaluated from a societal per-
spective, including direct and indirect costs.
Study design
This is a RCT in which collaborative care treatment for
MDD will be compared to CAU in the occupational
health setting. Randomisation will be at patient level.
Patients allocated to the intervention group will be
referred to the OP care manager in order to receive multi-
disciplinary treatment based on the collaborative care
framework. For their sick leave, they will receive the usual
care from their company's OP. Patients allocated to the
usual care group will not be referred to the OP care man-
ager and only receive sickness certification by their regular
OP as CAU (see Figure 1 for a flowchart of the partici-
pants). The intervention cannot be blinded, because the
patients will be aware of the allocation to either the inter-
vention group or the usual care group. Nevertheless, all
patient data will be obtained from self-report question-
naires, in order to exclude the possibility of interviewer
bias. Since the OP-care managers will have patients in the
intervention group only, it is not expected that they will
influence the outcome of the intervention in the usual
care group, so that contamination will not occur.
Recruitment of OPs
OP-care managers will be recruited in collaboration with
ArboNed, a large occupational health care service in the
Netherlands. The OP-care managers will receive training
in care management (including PST and the workplace
intervention) before they can occupy the role of care man-
ager in the collaborative care intervention.
Recruitment of patients
This study will focus on employees who have been on sick
leave for between 4 and 12 weeks. By choosing this dura-
tion of sick leave to intervene in, we try to prevent a tran-
sition to long-term absenteeism. Research on low back
pain (LBP) suggests that treatment at a sub-acute phase
(4–12 weeks) is more effective at preventing chronic disa-
bility than attempts to treat it when it has already become
chronic. "The longer a worker is off work with LBP, the
lower their chances of ever returning to work" [38]. In the
present study we assume a comparable 'window of oppor-
tunity' for MDD and therefore choose the abovemen-
tioned duration of sick leave. The restriction of aPage 3 of 12
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Flowchart of the participantsigure 1
Flowchart of the participants. PHQ-9: Depression scale of the Patiënt Health Questionnaire, MINI: MINI-International 
Neuropsychiatric Interview.
      Patients approached who: 
x are on sick leave between 4 and 12 
weeks, and 
x do not have the prospect of full return to 
work yet 
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including too many patients with spontaneous recovery.
The present study does not focus on burn-out or the broad
concept of distress, which both are common health prob-
lems in working populations, but on MDD in particular.
Symptoms of distress are fatigue, apathy, irritability, ten-
sion, concentration problems and insomnia [39,40].,
which are also common symptoms in MDD. Also, burn-
out and MDD can overlap, for instance the risk of MDD is
greater when burn-out is severe, compared to mild or no
burn-out [41]. In this study, we will distinguish burnout
and distress from MDD by the presence of the two core
symptoms of MDD (anhedonia and depressive thoughts),
and we will diagnose MDD according to the DSM-IV cri-
teria [42].
Only patients whose company's OP is not an OP-care
manager will be invited for participation in order to avoid
contamination of effect. Patients on sick leave between 4
and 12 weeks will receive written information about the
study, an informed consent form and the baseline ques-
tionnaire. They are asked if they are willing to participate
in the study investigating mental problems and treatment
options in the occupational health setting. If they agree to
participate, they will be asked to sign the informed con-
sent form and to return it together with the completed
questionnaire to the researchers. Prior to this, the patients
will be sent a letter from their company OP in which the
upcoming study is announced. Also it is emphasized in
this letter that participation in the study is voluntary and
that refusal to participate will not have any consequences
for future guidance and sickness certification.
Patients who reach the cut-off score of 10 for moderate to
severe MDD on the PHQ-9 will be contacted by the
research assistant. The PHQ-9 is a brief, reliable instru-
ment that can be used to detect depressive disorders and
to monitor treatment response in primary care [43,44].
The research assistant will then arrange an appointment
with these patients for the administration of the mini-
International Neuropsychiatric Interview (MINI) by tele-
phone for DSM-IV classification [45,46] If a patient meets
the DSM-IV criteria for MDD according to the MINI, the
patient will be included in the study and after a second
informed consent is obtained, the patient will be ran-
domised. The patient will be excluded from the study if
MDD is not confirmed by the MINI.
Patient exclusion criteria
Patients who are suicidal, psychotic or with a primary
diagnosis of substance abuse or dependence, as assessed
by the MINI interview, will be excluded from the study.
Also, patients who do not have sufficient command of the
Dutch language to fill in the questionnaires and patients
who are pregnant will be excluded, as well as patients with
a legal involvement against their employer, e.g. due to a
conflict at work.
Treatment in the intervention group
Within the collaborative care model, the intervention will
contain the following elements: contracting, adherence-
enhancing techniques, manual-guided self-help, Problem
Solving Treatment (PST), a workplace intervention, active
monitoring and, depending on patient preference, pre-
scription of antidepressants according to a treatment algo-
rithm. These elements of the intervention run parallel to
each other. When starting with the treatment, the patient
starts with PST and the manual guided self help, and some
patients will also immediately want to start with antide-
pressant medication. The workplace intervention will be
fitted in during the first weeks of the intervention. The
treatment will be monitored every two weeks and, when
needed, will be intensified by adding an extra 6 sessions
of PST, or by adding antidepressant medication to the
treatment plan or by increasing or changing the antide-
pressant medication. The maximum duration of the inter-
vention will be 18 weeks. In case of non-remission, as
indicated by the PHQ-9 after 18 weeks, the patient will be
referred to specialised mental health care. Antidepressant
medication, when part of the treatment plan, will then be
handed over to the GP.
The care in the intervention group will be provided within
a multidisciplinary team comprising the OP-care manager
and a consultant psychiatrist. Care management accord-
ing to a protocol will be provided by the OP-care man-
ager. The OP-care manager can consult the psychiatrist if
needed and receives regular group supervision with other
OP-care managers by psychiatrists. The treatment process
follows an algorithm and is monitored by use of a web-
based tracking system.
The content of the interventions is described below:
a. Contracting
During the initial visit, the OP-care manager informs the
patient about MDD and treatment options. The patient
can choose for treatment with or without antidepressant
medication. The treatment plan is then jointly formulated
by the OP-care manager and the patient. During the inter-
vention phase, the patient is asked to fill in the PHQ-9
every two weeks in order to monitor progress.
b. Treatment algorithm for antidepressant medication
Antidepressant medication will be included in the treat-
ment plan if the OP-care manager and the patient con-
sider this necessary. In that case, the OP-care manager
prescribes the medication according to a treatment proto-
col [47]. The protocol incorporates well-defined step upPage 5 of 12
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PHQ9, and the results and any adverse effects will be dis-
cussed with the patient. The OP-care managers will be
supervised by the consultant psychiatrist.
c. Manual guided self-help
During the treatment, the patients work through a self-
help manual [48]. The manual is based on several existing
self-help books [49-51] and focuses on behavioural acti-
vation, negative thoughts, RTW and aspects of healthy
lifestyle. Willemse et al. found that primary care patients
with sub-clinical depression can benefit from self help
manuals for MDD [52]. In the present study, the self-help
manual is part of a complete intervention package and is
therefore meant as additional to the other components of
the intervention.
d. Adherence
Patient adherence will be improved by contracting and
psycho-education and by frequent follow-up appoint-
ments in which both adherence and progress will be eval-
uated. Provider adherence will be improved by
instructions from the researchers and by using a web-
based tracking system in which the treatment algorithm is
incorporated [35,53].
e. Problem Solving Treatment
Problem Solving Treatment (PST) is a brief, structured
psychological intervention that has been shown to be
effective in the management of MDD and stress related
disorders [54]. The problem-solving approach is based on
the common observation that emotional symptoms are
often induced by problems in daily life and it encourages
patients to formulate practical ways of dealing with such
problems. PST is client centred en focused on the here and
now. Patients will be taught to use their own skills and
resources to function better [54,55].
f. Workplace intervention
In treatment of depressive disorder so far, insufficient
attention has been paid to interventions aimed at Return
To Work (RTW) [56]. However, several studies confirm
the importance of taking into account the work environ-
ment and the roles of stakeholders involved in the RTW
process, regardless of the type of disorder [57-62]. The dis-
ability of an employee is influenced by the actions and
attitudes of the employee, the employer and the OP and
by interactions occurring between them. This requires a
case management approach, where disability manage-
ment takes place in the workplace and work adjustments
will be discussed as part of the RTW process. The work-
place intervention, in which the patient, the employer and
the OP-care manager participate, consists of a workplace
assessment and work adjustments [57]. The OP-care man-
ager's role is that of process mediator. The employer and
the patient separately point out barriers for RTW, brain-
storm for possible solutions and make a plan for imple-
mentation of solutions. The workplace intervention,
based on methods used in participatory ergonomics inter-
vention [58], relies on active participation and strong
commitment of both workers and employees in identify-
ing risk factors in the workplace and in choosing the most
appropriate solutions for these risks. Like PST, it is a client
centred intervention. This approach was proven effective
in reducing sick leave in patients with low back pain [57]
and appeared to be a useful tool in the assessment of men-
tal workload [58,63,64]. Recently, this workplace inter-
vention is adapted for stress related mental disorders
(SMDs), using an Intervention Mapping approach [65]. In
the present study, a modified version of the low back pain
participatory workplace intervention is developed and
will be used.
Dutch social insurance legislation
In the present study, the OP-care manager takes an active
role in curative care and is part of the treatment team.
Information about the treatment can only be given to the
company's OP after explicit approval of the patient. In the
Netherlands, treatment and sickness certification are sep-
arated since the beginning of the 20th century. The lack of
attention to working conditions by the curative sector and
the lack of communication and agreement between OPs
and the curative sector are consequences of this separation
[7,66]. Currently, there are however several studies on
their way to improve transmural occupational care and to
give the OP a more prominent position in primary care
[67,68]. In accordance with the separation in the Dutch
legislation, the treatment of MDD and the certification in
sickness absence are separated in this study. The com-
pany's OP remains responsible for the certification of sick-
ness absence and does not take part in the treatment team.
Communication between the company's OP and the
treating health professionals (including the OP-care man-
ager) in this study follows existing Dutch laws and guide-
lines [69,70].
Training and treatment integrity
Prior to the start of the intervention, the participating OP-
care managers receive training in collaborative care, care
management, PST and the workplace intervention. The
training is given by the researchers, who have previously
received training from the IMPACT research group in Seat-
tle [71] the developers of the collaborative care model.
Furthermore, during the intervention the adherence of the
OP-care managers to the intervention will be checked and,
with the consent of the patient, audio-tapes of PST ses-
sions will be discussed in group (peer) supervision ses-
sions together with other OP-care managers and the PST
trainer. Also, an instrument developed by Oxman et al. in
order to monitor treatment integrity will be used [72].Page 6 of 12
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In this study the effectiveness of the intervention is com-
pared to usual care. Usual care is protocolled according to
the OP guidelines of the Dutch Board for Occupational
Medicine. As there is considerable variation in the usual
care that is provided for patients with MDD, the actual
care that is provided in the CAU group (e.g. medication
and number of contacts with physicians) will be assessed
by questionnaire.
Data collection
Data will be collected by the Netherlands institute of men-
tal health and addiction, in cooperation with ArboNed.
Patients will be sent questionnaires and asked for their
participation and written informed consent. Measure-
ments will take place at baseline (T0), three (T1), six (T2),
nine (T3) and twelve months (T4) after inclusion. The
filled in questionnaires will be returned to the Nether-
lands Institute of Mental Health and Addiction by mail
and will be processed anonymously by the researchers.
Outcome parameters
1. The primary outcome measure is the severity of depres-
sive symptoms, as measured according to the PHQ
Depression sub-scale (PHQ9). This sub-scale is a brief and
valid instrument which measures each of the DSM-IV cri-
teria for MDD. Response is defined as a 50% reduction in
symptoms [30,43,44]. Remission is defined as < 5 points
on the PHQ9 [43,44].
2. The secondary outcome measure is lasting RTW,
defined as the duration of sick leave due to MDD in calen-
dar days from the day of randomization until full RTW in
own or other work with equal earnings, for at least 4
weeks without (partial or full) recurrence. Also assessed
will be the total numbers of days of sick leave, calculated
for the entire follow up period [57,73]. Data will be
derived from sick leave databases of ArboNed as well as
from the Trimbos/iMTA questionnaire for Costs associ-
ated with Psychiatric Illness (TiC-P) [74].
3. The tertiary outcome measure is the cost-utility of the
collaborative care intervention, compared to CAU. The
cost-utility is evaluated by relating the difference in direct
medical costs per patient receiving collaborative care or
CAU to the difference in terms of Quality Adjusted Life
Years (QALY) gained, which yields a cost per QALY esti-
mate. We will also estimate the cost per QALY including
the productivity costs. The costs will be assessed with the
TiC-P, a measure commonly applied in economic evalua-
tions of treatment in mental health care [74,75]. Quality
of life will be assessed with the EuroQol (EQ-5D) [76]
and the Short Form-36 (SF-36) [77], both of which are
validated instruments for the measurement of general
health-related quality of life. The EQ-5D descriptive sys-
tem consists of five dimensions: mobility, self-care, usual
activities, pain/discomfort and anxiety/depression. Each
has three levels: no problems, some problems and
extreme problems, thus defining a total of 243 (35) dis-
tinct health states. A study that was recently carried out in
the Netherlands evaluated the EQ-5D in a national set-
ting, resulting in the 'Dutch EQ-5D tariff'. The resulting
tariff is used to calculate utilities for EQ-5D health states
for the cost-utility analyses of health care programmes
and treatments [78,79]. Additionally, presenteeism will
be assessed with the presenteeism scale of the WHO
Health and Work Performance Questionnaire Short Form
(HPQ Short Form) [80].
Calculating the total direct medical costs with the TiC-P,
the total number of medical contacts (among which out-
patient visits, length of stay in hospital, use of medica-
tion) will be multiplied by unit costs of the corresponding
health care services. Reference unit prices for health care
services will be applied and adjusted to the year of the
study according to the consumer price index [81].
The second section of the TiC-P includes a short form of
the Health and Labour questionnaire (HLQ) for collecting
data on productivity losses, [82] the SF-HLQ which con-
sists of three modules that measure productivity losses:
absence from work, reduced efficiency at work and diffi-
culties with job performance [83]. The number of days of
absence from work and the actual costs of working hours
missed due to health-related problems are calculated on
the basis of the average value added per worker according
to age and gender per day and per hour, respectively. If
respondents indicate that they were absent from work
during the entire recall period, data will be collected from
the time when the period of long-term absence started.
This additional information will be used to calculate the
production losses according to the friction cost method
[84,85]. The friction cost method takes into account the
economic circumstances that limit the losses of productiv-
ity to society, which are related to the fact that a formerly
unemployed person may replace a person who has
become disabled [84].
Since the collaborative care intervention used in this study
is a new intervention, a unit price per session is not known
yet. To determine a reference price, a detailed cost-price
study will be performed. Therefore, we will perform meas-
urements of time for face-to-face contacts as well as indi-
rect time per contact (e.g. consultations of other
specialists) for a total of 20 sessions. Furthermore, we will
estimate overhead costs based on the information of the
financial department of the hospital. This will result in an
estimate of the actual costs per contact. The unit cost esti-
mate per contact will be used as a reference price per con-
tact for the collaborative care intervention.Page 7 of 12
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evaluated:
In addition to the PHQ-9, symptoms will also be assessed
with the Inventory for Depressive Symptomatology Self
Report (IDS-SR), measuring the severity of the symptoms
of MDD as well as remission [86]. Co-morbid chronic
medical illness will be measured with the CBS list, a ques-
tionnaire developed by the Dutch Central Department of
Statistics. Pain will be measured according to the SF-36
Pain scale.
Patient adherence will be assessed by means of a qualita-
tive questionnaire [53]. The treatment received in the
CAU group, assessed in patients, will be measured accord-
ing to the Scale Assessing Contacts between patients and
practitioners [53]. The working relationship between
patient and OP-care manager will be assessed by means of
the Patient-Doctor Relationship Questionnaire (PDRQ-9)
[87].
As a possible prognostic measure, potential work-related
psychosocial factors will be assessed by the Job Content
Questionnaire [88].
A process evaluation will be conducted with the first 35
cases who have been randomised in the intervention
group. Both quantitative and qualitative data on the
applicability, compliance, satisfaction and barriers to the
protocol will be gathered. Patient satisfaction with the
OP-care manager and the regular OP will be measured
with the Patient Satisfaction with Occupational Health
Services Questionnaire (PSOHQ) [89]. This evaluation
will take place 18 weeks after randomisation, which is the
maximum duration of the intervention.
Power calculations
The primary outcome measure is response (a 50% reduc-
tion in depressive symptoms). Based on previous work
[30], the expected response rate in depressive symptoms is
14,76% in the CAU group and 31,8% in the intervention
group. Power calculations have been made with the usual
alpha of 5% and power of 80%. In order to detect a stand-
ardized difference of 0.5 SD on the primary outcome
measure, which can be considered as a clinically relevant
difference, 2 × 63 patients will be needed, when taking
into account two-tailed testing. An improvement of more
than 5 points on the PHQ-9 can be considered as a clini-
cally relevant difference [43].
Analyses
a. Effectiveness on severity of depressive symptoms
All analyses will be performed at patient level. The data
will be analysed on an intention-to-treat basis, i.e. the
patients will remain in the group to which they were ran-
domly allocated at baseline. The analyses will include t-
tests, Chi-square tests and GLM Repeated measurement.
The effect size will be estimated by Chi square analysis
and described in Cohen's d. Possible confounders such as
age, gender, immigrant status, level of education and
treatment history will be included as variables in logistical
regression analysis.
b. Effectiveness on RTW
Kaplan Meier analyses will be used to describe the associ-
ation between the sick leave duration until full RTW and
the group allocation. To analyse the HR of the RTW rates
the Cox Proportional hazard model will be used.
c. Economic evaluation
The aim of the economic evaluation is to assess the cost
effectiveness of collaborative care for the treatment of
MDD in the occupational health setting. A cost utility
analysis will be applied, the results of which will be
expressed as a cost per QALY. The economic evaluation
will be made from a societal perspective. Therefore, all rel-
evant effects and costs due to resource utilisation within
the healthcare system (direct medical costs) and costs due
to production losses (productivity costs) will be included.
If there is missing data on costs and/or effects, and the
additional uncertainty it introduces, multiple imputation
will be used [90], and the Monte Carlo Markov Chain
(MCMC) approach will be used to impute the missing val-
ues. The uncertainty will be assessed using bootstrapping,
and the results will be presented in acceptability curves
[91].
For the economic evaluation, the effects will be measured
according to utility scores. In addition to the clinical out-
come parameters, utility scores will supply additional
information about the impact of collaborative care treat-
ment for MDD compared to CAU on the general health-
related quality of life. Furthermore, the results may be
compared to a broad range of other health care interven-
tions, also outside the field of mental health care.
Time-frame of the study
The duration of the entire study will be four years. The
preparatory period is 1 year. Subsequent to the approval
of the Medical Ethical Committee, OP-care managers are
recruited in collaboration with ArboNed and are trained
by the investigators. The inclusion phase will last 1,5 year,
and the follow-up moments will be 3, 6, 9 and 12 months
after inclusion, therefore the total intervention phase will
last 2,5 years. Data-analyses will take 6 months.
Ethical principles
The study has been designed and will be carried out in
accordance with the principles laid down in the HelsinkiPage 8 of 12
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2000). Participation in the study is voluntary. Written
informed consent will be obtained from all patients and
the patients will be explicitly informed about the fact that
they can withdraw their consent to participate at any time,
without any specific reason and with no negative conse-
quences with regard to their future medical treatment.
Patients who wish to withdraw from the study will con-
tinue to receive CAU. In addition, patients have the
opportunity to consult an objective expert who is not
involved in the study.
Patient names and other confidential information will be
treated according to the medical confidentiality rules, and
data will be separated from patient names. Each partici-
pant will be identified in the database by a number and a
code, and these codes are only available to the participat-
ing investigators. Furthermore, data related to the study
are stored on a protected server of the Netherlands insti-
tute of mental health and addiction, which can only be
accessed by the members of the research team. The study
protocol has been approved by the Medical Ethical Com-
mittee of the VU Medical Centre at August the third, 2007.
Discussion
The high prevalence and burden of MDD, the high level
of sickness absence among people with MDD and the neg-
ative consequences of prolonged sickness absence for
patients as well as society contribute to the relevance of
this study. Purpose of this study is to not only reduce
depressive symptoms, but also to achieve an earlier, long-
lasting RTW.
Comparison with other studies
Currently, collaborative care treatment for patients with
MDD is also being studied in the Netherlands in the pri-
mary care setting and the general hospital setting [92,93].
Transmural occupational care is currently being applied in
the Netherlands in the RCT of Lambeek et al. [94], in
which OP-care managers are responsible for the planning
and coordination of care in the treatment of patients with
chronic low back pain. In the RCT of van der Feltz et al.,
collaboration between OPs and psychiatrists is applied by
offering psychiatric consultation to OPs in case of patients
with common mental disorders [68].
Strengths and limitations
Innovative of this study is the new role of the OP as the
care manager in the treatment of MDD. A model for trans-
mural care, the collaborative care model, is applied with a
focus on RTW within the occupational health setting.
Because of the separation between treatment and sickness
certification in the Netherlands, patients are probably not
much used to this, neither are the OPs themselves. How-
ever, certification in sickness absence and treatment will
be provided by different OPs: the company OP and the
OP-care manager. Training and close supervision will be
provided to the OP-care managers and the OP-care man-
agers will discuss their role with the patients. Also, the
supervision and consultation of the psychiatrist and the
web-based tracking system will facilitate working with this
new model. Limitation of this study might be that in other
studies effects are often found on RTW and not at symp-
tom-level [16-18]. while our primary outcome measure is
the severity of depressive symptoms and RTW is our sec-
ondary. Another limitation of this study may be that, with
this study design, we will not be able to make inferences
about the effectiveness of the respective ingredients of the
collaborative care model (such as PST or the workplace
intervention), but only about the (cost)effectiveness of
the collaborative care model itself.
Policy implications
If the collaborative care intervention proves to be cost-
effective in the occupational health setting in the treat-
ment of MDD, wider implementation may well be feasi-
ble. Since the costs of MDD are for the most part due to
production loss [3,4]., implementation could be very rel-
evant not only for individual patients and employers but
also for the entire society. However, the fact that in Dutch
social insurance legislation treatment and sickness certifi-
cation are separated and countries differ in their level of
occupational health coverage [24], might limit generaliza-
tion to other countries.
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